NCT00521560View on ClinicalTrials.gov

A Study of Zevalin and Simultaneous Application of BEAM High-dose Chemotherapy Followed by Autologous Stem Cell Transplantation in Refractory and Relapsed Aggressive Non-Hodgkin Lymphomas

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

August 31, 2009

Study Completion Date

August 31, 2012

Conditions
Primary Non-Hodgkin-LymphomaRefractory Non-Hodgkin-LymphomaCD20+ Aggressive Non-Hodgkin's Lymphoma
Interventions
DRUG

Zevalin

"All applications of 90Y-Ibritumomab-Tiuxetan will be preceded by rituximab infusions at a dose of 250 mg/m2 at days -21 and day -14 (DL1) or day -12 (DL2) or day -10 (DL3-5), respectively.~High dose therapy will be given as BEAM"

Trial Locations (1)

37075

Institut für anwendungsorientierte Forschung und klinische Studien (IFS GmbH), Göttingen

All Listed Sponsors
lead

Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH

OTHER

NCT00521560 - A Study of Zevalin and Simultaneous Application of BEAM High-dose Chemotherapy Followed by Autologous Stem Cell Transplantation in Refractory and Relapsed Aggressive Non-Hodgkin Lymphomas | Biotech Hunter | Biotech Hunter